
Research &
Case Studies
Published Research Matters
BioSymetrics believes in data from beginning to end. This includes identifying opportunities to publish peer-reviewed research that validate our methods and discoveries. Here we also share pre-print and other types of research, given innovation sometimes moves faster than review cycles.

Large scale serum proteomics identifies proteins associated with Duchenne muscular dystrophy

The Lancet Study on COVID-19 featuring BioSymetrics

MOA Analysis for Rare Cancer (Pre-Print - bioRxiv)

Poster Presentation - MIT AI in Drug Discovery 2020

White Paper - Using AI to Discover Target and MOA Prediction Using HCI Screen

Paper - Using iterative Machine Learning (Contingent-AI) in a clinical setting

C reactive protein utilisation, a biomarker for early COVID-19 treatment

Drivers of Mortality in COVID ARDS Depend on Patient Sub-Type

Phenotype-driven identification of drug targets for post-COVID-19 anosmia

Poster Presentation – American Epilepsy Society (AES) 2022

Discriminating Acute Respiratory Distress Syndrome from other forms of respiratory failure via itera

Poster Presentation – Society for Laboratory Automation and Screening (SLAS) 2023 International Con (Copy)

Poster Presentation – Muscular Dystrophy Association Clinical & Scientific Conference March 19 – 22,

Toronto Machine Learning Summit (TMLS) presentation – June 12-14, 2023

MOA Miner Publication Case Study

Drivers of mortality in COVID ARDS depend on patient sub-type

Broad Institute Machine Learning in Drug Discovery Symposium
We’re here to share more.
More about what we’re working on and the results our partners have leveraged to increase understanding of disease and drive treatment decisions and therapeutic discoveries. Contact us to get in touch with our team and learn more.